where to next?, page-710

MC is already available to patients under the Special Access Scheme for the treatment of pain in chronic conditions (such as cancer etc). Substantial clinical trials have already been undertaken overseas on MC use with numerous successful end points achieved.

The science is not the issue here. It is the TGA approving products for their function and then permitting access to those products based on doctor requests. The sooner we have the finished final form product that delivers a stable and controlled dosage, the sooner product approval can be secured.

Request approval for MC under the SAS has been growing fast. It's a boom medical field.

A breakdown of the number of SAS Category B approvals by month for the previous 12 months, a 1800% increase or so YoY :

	Month	Number of SAS Category B approvals
1	February 2018	37
2	March 2018	54
3	April 2018	89
4	May 2018	132
5	June 2018	146
6	July 2018	188
7	August 2018	229
8	September 2018	237
9	October 2018	331
10	November 2018	567
11	December 2018	491
12	January 2019	672